Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'

Affiliations

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: mcbs@esmo.org.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
³ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁴ ESMO Head Office, Lugano, Switzerland.
⁵ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁶ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁸ Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Free article

Comment

N I Cherny et al. Ann Oncol. 2018.

Free article

. 2018 Mar 1;29(3):774-775.

doi: 10.1093/annonc/mdx747.

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: mcbs@esmo.org.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
³ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁴ ESMO Head Office, Lugano, Switzerland.
⁵ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁶ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁸ Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

No abstract available

Comment on

ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310. Ann Oncol. 2017. PMID: 28945867
Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies.
Del Paggio JC, Sullivan R, Hopman WM, Booth CM. Del Paggio JC, et al. Ann Oncol. 2018 Mar 1;29(3):773-774. doi: 10.1093/annonc/mdx721. Ann Oncol. 2018. PMID: 29112709 No abstract available.